Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nanox) (NASDAQ: NNOX) is a medical imaging technology company that combines imaging hardware, AI-based software, cloud infrastructure, and teleradiology services. The Nanox news feed on this page aggregates company press releases and market updates so readers can follow how Nanox advances its imaging platform, commercial strategy, and capital markets activity over time.
Nanox’s recent news highlights its Nanox.ARC and Nanox.ARC X multi-source digital tomosynthesis systems, including CE Mark certification for Nanox.ARC in Europe and FDA 510(k) clearance for Nanox.ARC X for general use in multiple clinical indications. Articles also cover distribution agreements and collaborations with partners in countries such as France, the Czech Republic, Greece, Romania, Serbia, Montenegro, and Bosnia and Herzegovina, reflecting efforts to expand clinical and commercial deployment of its imaging solutions.
Another key news theme is the growth of Nanox.AI and its imaging analytics portfolio. Press releases describe AI algorithms that analyze routine CT scans for early signs associated with chronic diseases and bone health solutions such as HealthVCF and HealthOST, which have been included in an Early Value Assessment by the UK National Institute for Health and Care Excellence. Updates also discuss acquisitions like VasoHealthcare IT, intended to support deployment of AI solutions across U.S. healthcare facilities.
Investors and analysts can also find financial results announcements, guidance updates, and details of registered direct offerings and other financings, as reported in Nanox’s press releases and related SEC filings. Together, these news items provide insight into Nanox’s commercialization progress, clinical collaborations, AI development roadmap, and capital strategy. Bookmark this page to access an organized stream of Nanox news, from product and partnership updates to financial and regulatory disclosures.
NANO-X IMAGING LTD (NNOX) has opened a new operational semiconductor chip fabrication plant in Yongin, South Korea. This facility will produce the Nanox.SOURCE chip, critical for the Nanox.ARC system, aiming to democratize access to X-ray technology globally. Covering 12,000 square meters, it is located near a semiconductor cluster, boosting manufacturing capabilities. The company plans to ramp up production by mid-2022, enhancing its vertical integration strategy amidst global supply chain challenges. This facility signifies a pivotal step in providing affordable medical imaging solutions.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced its fourth quarter results for 2021, reporting a revenue of $1.3 million compared to $0 for the same period in 2020. The non-GAAP gross profit stood at $0.2 million. The company strengthened its leadership and completed its technology transfer to Nanox Korea. However, a net loss of $22 million was reported, an increase from $19 million in Q4 2020, driven by merger-related expenses. Cash and equivalents decreased to $88.7 million, down from $213.5 million year-over-year.
Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its fourth quarter and full year results for 2021 on March 31, 2022, before the market opens. CEO Erez Meltzer and CFO Ran Daniel will lead a conference call at 8:30 a.m. ET to discuss the financial results and business updates. Interested parties can join the call by dialing specific numbers or via a webcast link, which will also be available on the Investor Relations section of the Nanox website. The company aims to innovate affordable digital X-ray technology for global medical imaging.
NANO-X IMAGING LTD (Nasdaq: NNOX) announces participation in two investor conferences in March 2022. The Chief Executive Officer, Erez Meltzer, and Chief Financial Officer, Ran Daniel, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15 at 9:20 am EST. They will also attend the Canaccord Genuity Musculoskeletal Conference in Chicago on March 22 at 3:00 pm CT. Webcast links for both presentations will be available on the Company's website.
NANO-X IMAGING LTD (NNOX) has announced a new CPT code from the American Medical Association for its HealthCCSng AI-enabled cardiac imaging solution, effective July 1, 2022. This code promotes the use of AI for detecting coronary artery calcium, a key indicator of cardiovascular disease, enhancing early detection and treatment opportunities. The code aims to streamline workflows for U.S. radiologists and improve patient care. The company has previously secured recognition for AI in imaging, indicating significant progress in medical technology.
NANO-X IMAGING LTD. (NNOX) announced that its subsidiary, USARAD Holdings, Inc., received re-certification from The Joint Commission with the Gold Seal of Approval. This certification underscores USARAD's commitment to high-quality and safe patient care, achieving compliance without conditions in an unannounced inspection. With a robust network of board-certified teleradiologists, USARAD aims to address the global radiologist shortage by integrating AI technology to enhance its imaging services. The company operates under an accelerating demand for outsourced imaging solutions.
NANO-X IMAGING LTD (NASDAQ: NNOX) will conduct a virtual tour of its Nanox.ARC at the RSNA Annual Meeting on December 1, 2021, at 11:30 am EST. The tour will be followed by an investor webinar at 2:00 pm EST the same day. This event will showcase the Nanox.ARC in a clinical setting from Shamir Medical Center, Israel. Interested participants can register for the meeting and will have access to a replay and Q&A session during the webinar.
For more details, visit www.nanox.vision.
NANO-X IMAGING LTD (NASDAQ: NNOX) reported its Q3 2021 results, ending the period with cash and marketable securities of $180.3 million. The company experienced a net loss of $13.5 million, up from $11.1 million in Q3 2020, primarily due to increased R&D and administrative expenses. Highlights include the completion of the Nanox AI merger and acquisitions of USARAD Holdings and MDWEB, aimed at enhancing its imaging technology and analytics capabilities. The company has signed MSaaS agreements for 6,500 Nanox.ARC units and expects to commercialize its technology in 2022.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced its participation in the 2021 Radiology Society of North America (RSNA) Annual Meeting from Nov. 28 to Dec. 2. Key highlights include the debut of the Nanox.ARC procedures at their virtual booth and a showcase of AI-enabled medical imaging solutions at booth 4949. A virtual tour from Shamir Medical Center will occur on Dec. 1 at 10:30 am CST. These advancements aim to enhance affordability and accessibility in medical imaging, aligning with their goal of improving early detection services.
NANO-X IMAGING LTD (NASDAQ: NNOX) has completed its merger with Zebra Medical Vision, Ltd., valued at approximately $110 million, with additional stock options worth up to $84 million contingent on performance milestones. The Company also acquired MDWEB, LLC and USARAD Holdings, Inc. for around $20 million in stock and cash, with potential additional payments of $10 million. These strategic acquisitions aim to enhance Nanox's AI-powered imaging solutions, addressing the global shortage of radiologists and improving healthcare delivery.